Abstract
IFN-α therapy has been a major development in the treatment of CML. Maturing experience has confirmed its ability to induce durable major cytogenetic remissions, which translate into durable long-term disease control, and change in the natural history of the disease. Future studies aimed at improving the percentage and quality of cytogenetic remissions by combining IFN-α therapy with other chemotherapeutic agents and/or biologicals are needed. The goal would be to identify strategies that can consistently achieve a major cytogenetic response rate of 40% to 50% in the general community setting with acceptable morbidity. Continued studies of the interactions between IFN-α therapy and transplant strategies will permit the optimization of treatment for each individual patient with CML.
Original language | English (US) |
---|---|
Pages (from-to) | 152-158 |
Number of pages | 7 |
Journal | Seminars in hematology |
Volume | 32 |
Issue number | 2 |
State | Published - 1995 |
ASJC Scopus subject areas
- Hematology